For laboratory research only.

Everything sold on peptidesth.com is supplied for in-vitro research and laboratory use. These materials are not drugs, supplements, or food. They are not intended for human or animal consumption, diagnostic use, or therapeutic use.

Please confirm you are 21 or older before continuing. Our research desk ships from Bangkok to qualified buyers in Thailand and worldwide.

Your acknowledgement is remembered on this device for 24 hours.

You’re about to view data for this compound.

This compound is supplied strictly for in-vitro research. It is not a medicine and is not intended for human or animal use. By continuing, you confirm you are 21 or older and accessing this information for laboratory purposes.
Thailand Peptides
Get in Contact
Research summary4 min read

BPC-157 research summary: mechanism, healing pathways, and primary literature

Curated summary of BPC-157 primary literature: VEGFR2 angiogenesis, Src-Caveolin-1-eNOS pathway, FAK-paxillin in tendon fibroblasts, gastric mucosal protection. PubMed-verified.

By TH Labs Research Desk · Research Editor ·
Key findings
  • VEGFR2 activation and upregulation in endothelial cells is BPC-157's most-direct angiogenic mechanism, documented in HUVEC tube-formation assays.
  • Src-Caveolin-1-eNOS signalling produces nitric-oxide-driven vasodilation, complementary to VEGFR2-driven new-vessel formation.
  • FAK-paxillin phosphorylation drives migration and survival of rat Achilles tendon fibroblasts in vitro.
  • Gastric mucosal protection was the original 1990s research thread; the BPC name reflects this Body Protection Compound history.
  • Human translation is limited: most musculoskeletal data is rat or rabbit, and clinical evidence is case reports and small open-label studies.

BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a naturally occurring protective sequence in human gastric juice. Three pathways have direct experimental support in the primary literature.

VEGFR2 activation drives angiogenesis

Hsieh and colleagues (2017, J Mol Med (Berl)) 3 demonstrated both direct VEGFR2 phosphorylation and transcriptional upregulation in HUVECs exposed to BPC-157. The combined effect amplifies endothelial responsiveness to endogenous VEGF and drives baseline angiogenic signalling. This pathway explains the angiogenic component of BPC-157's repair effect: injured tissue cannot heal without vascular supply, and increased VEGFR2 activity means faster capillary network formation in the wound bed.

Src-Caveolin-1-eNOS produces vasodilation

In their 2020 Scientific Reports paper 4, Hsieh's group characterised BPC-157's effect on endothelial nitric oxide synthase. The Src-Caveolin-1 axis works as follows: Src kinase phosphorylates caveolin-1, displacing it from eNOS and releasing eNOS from tonic inhibition. The result is NO production, smooth muscle relaxation, and increased local blood flow. This is complementary to VEGFR2-driven angiogenesis — new capillaries plus dilation make the bed functionally productive.

FAK-paxillin in tendon fibroblasts

Chang and colleagues' 2011 Journal of Applied Physiology paper 2 is the definitive reference for BPC-157's effect on tendon repair. Using primary rat Achilles tendon fibroblast cultures, they documented enhanced cell outgrowth, improved cell survival under apoptosis-inducing conditions, and accelerated migration in scratch-wound assays. The mechanism is FAK and paxillin phosphorylation at focal adhesions — converting receptor-level signalling into the cytoskeletal remodelling required for cell movement.

What is settled vs. exploratory

Settled: angiogenesis via VEGFR2 + NO pathway, cell migration via FAK-paxillin, gastric mucosal protection 15. Exploratory: neurotransmitter modulation, gut-brain axis effects, cardioprotection, and most organ-specific healing outside the gut and musculoskeletal system.

For the long-form treatment with full pathway-by-pathway analysis, see the BPC-157 mechanism deep-dive.

Thailand Peptides BPC-157 10 MG vial, clear glass with brushed aluminum cap and clear film label
Related peptide

BPC-157

Synthetic pentadecapeptide; studied for tendon-to-bone healing applications in preclinical (rodent) models.

Open BPC-157 product page →

Citations

  1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157, a novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PMID: 21548867
  2. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID: 21030672
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID: 27847966
  4. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020. PMID: 33051481
  5. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID: 34267654

All references verified against PubMed via NCBI E-utilities.

Research desk
Questions about BPC-157? WhatsApp the Bangkok research desk. Pricing, COA, and protocol questions handled in-chat.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

This summary draws on the full-length article at /articles/bpc-157-mechanism-deep-dive. The article is the canonical long-form treatment; this page is the research-summary re-presentation.